Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.

Li Y, Xue K, Hu R, Hu X, Guo R, Guo H, Li G

American journal of cardiovascular drugs : drugs, devices, and other interventions10 Jun 2025

PMID40493329DOI10.1007/s40256-025-00738-9PepBankPUB-40493329

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in obese populations, semaglutide significantly reduced systolic blood pressure versus control (mean difference - 2.90).
In plain wordsAcross trials in people with obesity, semaglutide lowered systolic blood pressure more than control.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure, all trials
Study
n = 15,347
Comparator
Control group
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Mean difference SBP
−2.9 NA
semaglutide versus control
Source sentences
Summary
the semaglutide group significantly reduced systolic blood pressure (SBP) (mean difference [MD] - 2.90, 95% confidence interval [CI] - 3.70 to - 2.11; P < 0.01
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science.
Summary · context
A total of 22 studies involving 15,347 participants were included in this meta-analysis.
Report a problemFND-4049332901
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in obese populations, semaglutide significantly reduced diastolic blood pressure versus control (mean difference - 0.86).
In plain wordsAcross trials in people with obesity, semaglutide lowered diastolic blood pressure more than control.
Peptide
Semaglutide
Outcome
DecreaseDiastolic blood pressure, all trials
Study
n = 15,347
Comparator
Control group
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Mean difference DBP
−0.86 NA
semaglutide versus control
Source sentences
Summary
and diastolic blood pressure (DBP) (MD - 0.86, 95% CI - 1.34 to - 0.38; P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science.
Summary · context
A total of 22 studies involving 15,347 participants were included in this meta-analysis.
Report a problemFND-4049332902
03HumanSystematic reviewEfficacy outcome
In diabetic people with obesity, semaglutide reduced systolic blood pressure (- 1.87), less than in non-diabetic people.
In plain wordsIn people with obesity and diabetes, semaglutide lowered systolic blood pressure, by less than in people without diabetes.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure, diabetic subgroup
Study
n: not reported in source
Comparator
Control group
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Mean difference SBP
−1.87 NA
diabetic subgroup
Source sentences
Summary
Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP (- 1.87, 95% CI - 2.67 to - 1.06, vs - 5.02, 95% CI - 6.10 to - 3.94) and DBP (- 0.43, 95% CI - 0.89 to 0.02, vs - 1.96, 95% CI - 3.12 to - 0.80) in non-diabetic populations.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science.
Summary · context
A total of 22 studies involving 15,347 participants were included in this meta-analysis.
Report a problemFND-4049332903
04HumanSystematic reviewEfficacy outcome
In non-diabetic people with obesity, semaglutide reduced systolic blood pressure (- 5.02), more than in diabetic people.
In plain wordsIn people with obesity but without diabetes, semaglutide lowered systolic blood pressure, by more than in people with diabetes.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure, non-diabetic subgroup
Study
n: not reported in source
Comparator
Control group
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Mean difference SBP
−5.02 NA
non-diabetic subgroup
Source sentences
Summary
Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP (- 1.87, 95% CI - 2.67 to - 1.06, vs - 5.02, 95% CI - 6.10 to - 3.94) and DBP (- 0.43, 95% CI - 0.89 to 0.02, vs - 1.96, 95% CI - 3.12 to - 0.80) in non-diabetic populations.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science.
Summary · context
A total of 22 studies involving 15,347 participants were included in this meta-analysis.
Report a problemFND-4049332904
05HumanSystematic reviewEfficacy outcome
In diabetic people with obesity, the semaglutide reduction in diastolic blood pressure (- 0.43; 95% CI - 0.89 to 0.02) was not significant.
In plain wordsIn people with obesity and diabetes, semaglutide did not clearly change diastolic blood pressure.
Peptide
Semaglutide
Outcome
No significant changeDiastolic blood pressure, diabetic subgroup
Study
n: not reported in source
Comparator
Control group
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Mean difference DBP
−0.43 NA
diabetic subgroup
Source sentences
Summary
Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP (- 1.87, 95% CI - 2.67 to - 1.06, vs - 5.02, 95% CI - 6.10 to - 3.94) and DBP (- 0.43, 95% CI - 0.89 to 0.02, vs - 1.96, 95% CI - 3.12 to - 0.80) in non-diabetic populations.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science.
Summary · context
A total of 22 studies involving 15,347 participants were included in this meta-analysis.
Report a problemFND-4049332905
06HumanSystematic reviewEfficacy outcome
In non-diabetic people with obesity, semaglutide reduced diastolic blood pressure (- 1.96), more than in diabetic people.
In plain wordsIn people with obesity but without diabetes, semaglutide lowered diastolic blood pressure.
Peptide
Semaglutide
Outcome
DecreaseDiastolic blood pressure, non-diabetic subgroup
Study
n: not reported in source
Comparator
Control group
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Mean difference DBP
−1.96 NA
non-diabetic subgroup
Source sentences
Summary
Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP (- 1.87, 95% CI - 2.67 to - 1.06, vs - 5.02, 95% CI - 6.10 to - 3.94) and DBP (- 0.43, 95% CI - 0.89 to 0.02, vs - 1.96, 95% CI - 3.12 to - 0.80) in non-diabetic populations.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science.
Summary · context
A total of 22 studies involving 15,347 participants were included in this meta-analysis.
Report a problemFND-4049332906
07HumanSystematic reviewEfficacy outcome
In the meta-analysis, semaglutide 2.4 mg significantly lowered systolic blood pressure (mean difference - 4.31).
In plain wordsAcross trials, the higher semaglutide dose of 2.4 mg lowered systolic blood pressure.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure at 2.4 mg
Study
n: not reported in source
Comparator
Control group
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Measurements
Mean difference SBP
−4.31 NA
semaglutide 2.4 mg
Source sentences
Summary
The higher dose of semaglutide (2.4 mg) was found to significantly lower SBP (MD - 4.31, 95% CI - 5.18 to - 3.44)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science.
Summary · context
A total of 22 studies involving 15,347 participants were included in this meta-analysis.
Report a problemFND-4049332907
08HumanSystematic reviewEfficacy outcome
In the meta-analysis, semaglutide 2.4 mg significantly lowered diastolic blood pressure (mean difference - 1.84).
In plain wordsAcross trials, the higher semaglutide dose of 2.4 mg lowered diastolic blood pressure.
Peptide
Semaglutide
Outcome
DecreaseDiastolic blood pressure at 2.4 mg
Study
n: not reported in source
Comparator
Control group
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Measurements
Mean difference DBP
−1.84 NA
semaglutide 2.4 mg
Source sentences
Summary
and DBP (MD - 1.84, 95% CI - 2.70 to - 0.98), although mild heterogeneity was present.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials on the effect of semaglutide on blood pressure regulation published from the inception of the databases to October 2024 were searched for in PubMed, Embase, the Cochrane Library, and Web of Science.
Summary · context
A total of 22 studies involving 15,347 participants were included in this meta-analysis.
Report a problemFND-4049332908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.